The Food and Drug Administration on Tuesday released a warning letter that it sent to medical device company Dexcom on March 4 citing quality issues at the facilities responsible for testing its ...

FOX21’s Carolynn Felling, a Type One Diabetic herself, said since she last covered the shortage, she has been able to get her ...

A Dexcom is responsible for monitoring blood glucose levels for both Type One and Type Two diabetes, and it has saved many lives. “It messes up things at the clinic with my endocrinologist ...

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Investors with a lot of money to spend have taken a bullish stance on DexCom DXCM. And retail traders should know. We noticed this today when the positions showed up on publicly available options ...

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0% ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to ...